eFFECTOR is made up of industry veterans who have played crucial roles in drug discovery and development. But more importantly, we are a team that knows patients deserve more effective treatment options. And we believe these are within reach.
What are selective translation regulator inhibitors?
Cancer is a complex, aggressive disease driven by multiple factors that propel uncontrolled growth and enable it to evolve to evade existing therapies.
We are pioneering a new class of cancer therapies called selective translational regulator inhibitors (STRIs) –designed to outsmart cancer’s complexity, create better outcomes for patients and block the production of many cancer-driving proteins simultaneously.
Interested in joining a team that’s working to outsmart cancer?